Additionally, in the case of NMOSD, it is crucial that it is differentiated from MS because the treatment options differ and some MS therapies such as IFN-β, natalizumab, and oral fingolimod, can even worsen NMO.[73] ON in MOGAD, however, generally had better visual outcomes and responds better to corticosteroids. This evidence concerns the gene IFNB1 and myeloid sarcoma.